Intellia Therapeutics Investor Presentation — February 2021

Document content

Intellia Therapeutics’ Legal Disclai mer

This presentation contains “forward-l ooking statements” of Intellia Thera peutics, Inc. (“Intellia”, “we” or “our”) within the meaning of the Private Securities Litigation Reform Act

of 1995. These forward-l ooking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations regard ing our: being able

to enroll and dose the necessary subjects in our clinical studies for NTLA-2001 for the treatment of transthyretin amyloidosis (“ATTR”), provide timing on the first expected data

readout, and successfully submit addition al regula tory applications in other countries ; ability to evaluate NTLA-2001 in a broader ATTR populat ion; the ability to demonstrate

NTLA-5001 as a potenti al best-in-class engineered T cell therapy desig ned to treat all genetic subtypes of acute myeloid leukemia (“AML”); plans to submit an investigat ional

new drug (“IND”) application or equivalent regulato ry application for NTLA-5001 in mid-2021; expectations of evaluating the safety and activity of NTLA-5001 in patients with

persistent or recurrent AML who have previously received first-line therapies ; plans to evaluate the potenti al use of NTLA-5001 to treat WT1-p ositive solid tumors in precli nical

studies; plans to submit an IND or equivalent regulatory application for NTLA-2 002 in the second half of 2021; expectations of evaluating safety, tolerability and measures of

activities of NTLA-2 002 in patients with hereditary angioedema (“HAE”); plans to nominate at least one additional development candidate in 2021; plans to advance and

complete preclinical studies for our programs ; development of our modular platform to advance our complex genome editing capab ilities ; further development of our propr ietary

genome editing tools for research and therapeutic development sequen tial editing; presentation of additi onal data at upcoming scientific conferences, and other preclinical data

in 2021; advancement and expansion of our CRISPR/Cas 9 technology to devel op human therap eutic products, as well as our ability to maint ain and expand our related

intellectual property portfolio; ability to demonstrate our platform’s modularity and replicate or apply results achieved in preclinical studies, including those in our ATTR, AML,

and HAE programs, in any future studies, including human clinical trials; ability to develop other in vivo or ex vivo cell therapeutic s of all types, and those targeting Wilms’

Tumor 1 ("WT1") in AML in particular, using CRISPR/Cas9 technology; ability to optimize the impact of our collaborations on our development programs , including but not limited to